Other languages Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-07 EDT			5-day change	1st Jan Change
1,527 ^JPY	-0.13%		+0.16%	+8.68%

03-26	Santen Pharmaceutical to Cancel 12 Million Treasury Shares	MT
03-25	Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santen Pharmaceutical to Cancel 12 Million Treasury Shares	03-25
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	03-25
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	02-08
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-08
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	01-07
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	12-04
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	11-08
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	11-07
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	11-07
ETF der Woche: Back to the Roots	23-09-29
ETF de la semaine : Retour aux fondamentaux	23-09-28
ETF van de week: terug naar de basis	23-09-28
L'ETF della settimana: ritorno ai fondamentali	23-09-28
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-09-19
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024	23-08-03
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-08-03
Visiox Pharma Enters into A Definitive Agreement with Santen Pharmaceutical Co., Ltd to License OMLONTI	23-07-19
Bank Earnings Leave Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday	23-07-19
Harrow Health Acquires Certain US, Canada Rights to Santen Pharmaceutical's Ophthalmic Portfolio	23-07-19
Santen Pharmaceutical Co., Ltd. Signs Licensing Agreements	23-07-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Other languages

Filters